BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20684143)

  • 1. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
    Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
    J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
    J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).
    Cassano N; Loconsole F; Galluccio A; Miracapillo A; Pezza M; Vena GA
    Int J Immunopathol Pharmacol; 2006; 19(1):225-9. PubMed ID: 16569361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Our experience with etanercept in the treatment of psoriasis.
    Kokelj F; Miertusova Tothova S; Patamia M; Trevisan G
    Acta Dermatovenerol Croat; 2006; 14(4):241-5. PubMed ID: 17311738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term etanercept in pediatric patients with plaque psoriasis.
    Paller AS; Siegfried EC; Eichenfield LF; Pariser D; Langley RG; Creamer K; Kricorian G
    J Am Acad Dermatol; 2010 Nov; 63(5):762-8. PubMed ID: 20605256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
    Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
    J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent etanercept therapy in pediatric patients with psoriasis.
    Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
    J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
    Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
    J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.